Online citations, reference lists, and bibliographies.
← Back to Search

Heart Dosimetry Is Correlated With Risk Of Radiation Pneumonitis After Lung-Sparing Hemithoracic Pleural Intensity Modulated Radiation Therapy For Malignant Pleural Mesothelioma.

E. Yorke, A. Jackson, L. Kuo, A. Ojo, Kelly Panchoo, P. Adusumilli, M. Zauderer, V. Rusch, A. Shepherd, A. Rimner
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE To determine clinically helpful dose-volume and clinical metrics correlating with symptomatic radiation pneumonitis (RP) in malignant pleural mesothelioma (MPM) patients with 2 lungs treated with hemithoracic intensity modulated pleural radiation therapy (IMPRINT). METHODS AND MATERIALS Treatment plans and resulting normal organ dose-volume histograms of 103 consecutive MPM patients treated with IMPRINT (February 2005 to January 2015) to the highest dose ≤50.4 Gy satisfying departmental normal tissue constraints were uniformly recalculated. Patient records provided maximum RP grade (Common Terminology Criteria for Toxicity and Adverse Event version 4.0) and clinical and demographic information. Correlations analyzed with the Cox model were grade ≥2 RP (RP2+) and grade ≥3 RP (RP3+) with clinical variables, with volumes of planning target volume (PTV) and PTV-lung overlap and with mean dose, percent volume receiving dose D (VD), highest dose encompassing % volume V, (DV), and heart, total, ipsilateral, and contralateral lung volumes. RESULTS Twenty-seven patients had RP2+ (14 with RP3+). The median prescription dose was 46.8 Gy (39.6-50.4 Gy, 1.8 Gy/fraction). The median age was 67.6 years (range, 42-83 years). There were 79 men, 40 never-smokers, and 44 with left-sided MPM. There were no significant (P≤.05) correlations with clinical variables, prescription dose, total lung dose-volume metrics, and PTV-lung overlap volume. Dose-volume correlations for heart were RP2+ with VD (35 ≤ D ≤ 47 Gy, V43 strongest at P=.003), RP3+ with VD (31 ≤ D ≤ 45 Gy), RP2+ with DV (5 ≤ V ≤ 30%), RP3+ with DV (15 ≤ V ≤ 35%), and mean dose. Significant for ipsilateral lung were RP2+ with VD (38 ≤ D ≤ 44 Gy), RP3+ with V41, RP2+ and RP3+ with minimum dose, and for contralateral lung, RP2+ with maximum dose. Correlation of PTV with RP2+ was strong (P<.001) and also significant with RP3+. CONCLUSIONS Heart dose correlated strongly with symptomatic RP in this large cohort of MPM patients with 2 lungs treated with IMPRINT. Planning constraints to reduce future heart doses are suggested.
This paper references
10.1016/J.IJROBP.2007.05.065
The impact of heart irradiation on dose-volume effects in the rat lung.
P. van Luijk (2007)
10.1016/S0360-3016(98)90033-5
A comprehensive three-dimensional radiation treatment planning system.
R. Mohan (1988)
10.1016/S1470-2045(14)71207-0
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
J. Bradley (2015)
10.1016/j.lungcan.2013.10.013
Radical pleurectomy/decortication followed by high dose of radiation therapy for malignant pleural mesothelioma. Final results with long-term follow-up.
E. Minatel (2014)
10.1158/0008-5472.CAN-05-0786
Radiation damage to the heart enhances early radiation-induced lung function loss.
P. van Luijk (2005)
10.1016/j.ijrobp.2009.06.091
Radiation dose-volume effects in the lung.
L. Marks (2010)
10.3109/0284186X.2010.521192
Heart irradiation as a risk factor for radiation pneumonitis
E. Huang (2011)
10.1200/JCO.2016.67.2675
Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma.
A. Rimner (2016)
10.1016/J.IJROBP.2007.03.011
Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma.
D. Rice (2007)
10.1016/S0167-8140(03)00132-4
Loco-regional differences in pulmonary function and density after partial rat lung irradiation.
E. M. Wiegman (2003)
10.1016/J.IJROBP.2005.03.026
Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study.
E. Yorke (2005)
10.3109/0284186X.2012.718093
A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis
I. Vogelius (2012)
10.1016/j.ijrobp.2014.05.032
Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma.
A. Rimner (2014)
10.1097/JTO.0b013e318272601f
Tomotherapy after Pleurectomy/Decortication or Biopsy for Malignant Pleural Mesothelioma Allows the Delivery of High Dose of Radiation in Patients with Intact Lung
E. Minatel (2012)
10.1016/j.ijrobp.2011.09.027
Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma.
K. Rosenzweig (2012)
10.1016/J.ATHORACSUR.2007.04.076
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma.
D. Rice (2007)
10.1118/1.598202
A gradient inverse planning algorithm with dose-volume constraints.
S. Spirou (1998)
10.1016/j.prro.2014.11.005
Early experience with intensity modulated proton therapy for lung-intact mesothelioma: A case series.
H. Pan (2015)
10.3978/j.issn.2225-319X.2012.10.07
Novel radiation therapy approaches in malignant pleural mesothelioma.
A. Rimner (2012)
10.1016/j.ijrobp.2009.11.006
Proton therapy for malignant pleural mesothelioma after extrapleural pleuropneumonectomy.
J. Krayenbuehl (2010)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar